12Nov 2021
A model‐based simulation of glycaemic control and body weight when switching from semaglutide to 3.0‐ and 4.5‐mg doses of once‐weekly dulaglutide

A model‐based simulation of glycaemic control and body weight when switching from semaglutide to 3.0‐ and 4.5‐mg doses of once‐weekly dulaglutide

To evaluate HbA1c and body weight changes when semaglutide 0.5‐ or 1.0‐mg once‐weekly (QW) is switched to dulaglutide 3.0‐ or 4.5‐mg QW via exposure‐response modelling. HbA1c and body weight time‐course models were developed and validated with data from the SUSTAIN 1 to 10 trials for semaglutide and the AWARD‐11 trial for dulaglutide. Simulations were conducted for HbA1c and body weight over 52 weeks. In the initial 26 weeks, semaglutide was initiated at 0.25‐mg and titrated to 0.5‐ or 1.0‐mg QW via 4‐weekly stepwise titration, followed by 26 weeks of dulaglutide initiated at 0.75‐ or 1.5‐mg QW and escalated to 3.0‐ or 4.5‐mg QW via 4‐weekly stepwise titration...

  • #endo-diabetology

Like

Save

Share